Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 19;2(3):550-567.
doi: 10.20517/cdr.2019.58. eCollection 2019.

Long non-coding RNAs regulation of therapeutic resistance

Susan Tsang  1   2 , Tajhal Patel  2 , Jason T Yustein  1   2
Affiliations
Review

Long non-coding RNAs regulation of therapeutic resistance

Susan Tsang et al. Cancer Drug Resist. .

Abstract

Non-protein coding RNAs have emerged as a regulator of cell signaling and cancer progression through regulation of cell proliferation, metastatic burden, and cancer stem cell capacity. A subtype of non-protein coding RNA is long non-protein coding RNA (lncRNA). Besides their aforementioned roles in cancer cell biology, dysregulation of lncRNAs contribute to resistance to therapeutic treatments. A couple of important therapeutic classes are chemotherapy and targeted/hormone therapies. This review highlights the variety of malignancies affected by lncRNA dysregulation and the underlying mechanism causing therapeutic resistance.

Keywords: Long non-protein coding RNA; and microRNA sponge; cancer; chemotherapeutic resistance; hormone therapy; target therapeutics.

PubMed Disclaimer

Conflict of interest statement

All authors declared that there are no conflicts of interest.

Figures

Figure 1
Figure 1
Schematic of the lncRNAs that contribute to therapeutic resistance in a variety of malignancies. The arrows represents the direction of dysregulation when cancer is in a therapeutic resistant state
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. DeVita VT Jr, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68:8643–53. doi: 10.1158/0008-5472.CAN-07-6611. - DOI - PubMed
    1. Shewach DS, Kuchta RD. Introduction to cancer chemotherapeutics. Chem Rev. 2009;109:2859–61. doi: 10.1021/cr900208x. - DOI - PMC - PubMed
    1. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–78. doi: 10.1016/j.ejphar.2014.07.025. - DOI - PMC - PubMed
    1. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 2009;69:223–40. doi: 10.2165/00003495-200969020-00006. - DOI - PubMed
    1. Hagner N, Joerger M. Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res. 2010;2:293–301. doi: 10.2147/CMR.S10043. - DOI - PMC - PubMed

LinkOut - more resources